Prescient Therapeutics (ASX:PTX) resolved the technical difficulties facing its OmniCAR program by creating a new generation of improved variants, according to a Thursday Australian bourse filing.
OmniCAR is a CAR(chimeric antigen receptor)-cell platform, that enables controllable T-cell activity and multi-antigen targeting with a single-cell product.
It observed that OmniCAR T-cells unarmed with antigen binders were demonstrating unexpected activity, which ran counter to "the modular, controllable thesis" of the program.
It developed several OmniCAR variants over 2024 in collaboration with the Peter McCallum Cancer Center and Australia's Commonwealth Scientific and Industrial Research Organization, that overcame the issues observed with the previous OmniCAR version in preliminary in vitro and in vivo testing.
When armed with binders, these new variants demonstrated highly effective tumor-killing activity in mice with Her2-positive tumors. The duration of efficacy was more than that of the previous version of the platform.
It will further evaluate these variants in 2025.
The firm's shares rallied 13% in trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。